BioSpace News Archive

The Centers for Medicare and Medicaid Services (CMS) has assigned an HCPCS Level II code to Omegaven®, the newest parenteral nutrition product introduced in the United States by Fresenius Kabi.

AirAvant Medical, a South Florida-based medical device company, announced that its new Bongo Rx sleep apnea therapy device has been nominated for an Edison Award™.

Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training, announced today that the New Jersey Board of Nursing has reported 94% of Nursing graduates from its Paramus, NJ campus have passed a key licensing exam on their first attempt.

IBH Population Health Solutions (Integrated Behavioral Health, Inc.) announced today that an accomplished healthcare executive has joined the company to help accelerate its nationwide growth.

Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, today announced that it has received $2.6 million in private financing to fund the commercialization of Catasyn™ Advanced Technology Wound Hydrogel and SynePure™ Wound Cleanser, two U. S. Food and Drug Administration (FDA) 510(k)-cleared products that form part of Synedgen’s Wound Care portfolio.

StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced the launch of Corplex, the first of two umbilical cord derived products launching this year.

AMN Healthcare Services, Inc. (NYSE: AMN), the nation’s leading innovator in healthcare talent solutions and staffing services, today announced a definitive agreement to acquire Stratus Video for a purchase price of $475 million

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer its securities in an underwritten public offering.

CONMED Corporation (NASDAQ: CNMD) today announced that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the NASDAQ Global Market.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced it has completed a Series C financing which raised $30 million in new funds.